Adele J Baker 26th Lorne Cancer Conference 2014

Abstracts this author is presenting:

• Cyclin-dependent kinase inhibitor, Dinaciclib induces anti-tumour activity of mixed-lineage leukemia-AF9 surpassing known targeted therapies for this disease. — Poster Session 1